NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LGND

Ligand Pharmaceuticals, Inc

Jul 11 • 04:00PM ET

121.70

Dollar change -3.28
Percentage change -2.62	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR IWM VTI VB VXF VBR SPSM IWN DFAT IJT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-7.12	Insider Own	2.59%	Shs Outstand	19.28M	Perf Week	6.21%
Market Cap	2.35B	Forward P/E	17.41	EPS next Y	6.99	Insider Trans	0.62%	Shs Float	18.79M	Perf Month	7.30%
Enterprise Value	2.14B	PEG	-	EPS next Q	1.42	Inst Own	97.86%	Short Float	6.32%	Perf Quarter	17.19%
Income	-132.62M	P/S	12.94	EPS this Y	6.60%	Inst Trans	2.95%	Short Ratio	9.88	Perf Half Y	10.33%
Sales	181.49M	P/B	2.95	EPS next Y	14.27%	ROA	-14.58%	Short Interest	1.19M	Perf YTD	13.58%
Book/sh	41.27	P/C	11.24	EPS next 5Y	11.93%	ROE	-16.56%	52W High	129.90 -6.31%	Perf Year	32.70%
Cash/sh	10.83	P/FCF	46.52	EPS past 3/5Y	- -	ROIC	-16.60%	52W Low	90.29 34.79%	Perf 3Y	96.81%
Dividend Est.	-	EV/EBITDA	102.76	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	74.61%	Volatility	3.69% 3.11%	Perf 5Y	65.70%
Dividend TTM	-	EV/Sales	11.81	EPS Y/Y TTM	-230.86%	Oper. Margin	-9.16%	ATR (14)	3.86	Perf 10Y	91.28%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	5.02	Sales Y/Y TTM	53.40%	Profit Margin	-73.07%	RSI (14)	64.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.27	EPS Q/Q	-146.54%	SMA20	5.17%	Beta	0.88	Target Price	143.88
Payout	-	Debt/Eq	0.01	Sales Q/Q	46.34%	SMA50	11.31%	Rel Volume	0.89	Prev Close	124.98
Employees	68	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	9.74%	Avg Volume	120.26K	Price	121.70
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.76% 17.12%	Trades		Volume	106,482	Change	-2.62%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169

Show Previous Ratings

Today 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
07:00AM	Loading…
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
09:35AM	Loading…
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
04:01PM	Loading…
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
KOZARICH JOHN W	Director	Jan 17 '25	Option Exercise	52.30	2,406	125,834	46,181	Jun 02 08:05 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM
Espinoza Octavio	Chief Financial Officer	Dec 23 '24	Sale	116.37	2,104	244,850	20,647	Dec 26 08:32 PM
Espinoza Octavio	Officer	Dec 23 '24	Proposed Sale	116.37	2,104	244,851		Dec 23 08:19 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Option Exercise	52.30	2,406	125,834	31,921	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Sale	123.65	2,406	297,502	29,515	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 26 '24	Proposed Sale	119.19	2,406	286,771		Nov 27 04:44 PM
Korenberg Matthew E	Officer	Nov 11 '24	Proposed Sale	120.33	32,183	3,872,684		Nov 12 10:25 AM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Option Exercise	52.27	2,000	104,540	24,534	Sep 25 08:54 PM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Sale	99.60	2,000	199,201	22,534	Sep 25 08:54 PM
Espinoza Octavio	Chief Financial Officer	Sep 20 '24	Sale	103.94	1,275	132,518	24,610	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Option Exercise	52.72	9,772	515,227	60,549	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Option Exercise	49.99	4,982	249,050	57,052	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Sale	101.22	9,772	989,121	50,777	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Sale	104.10	6,275	653,238	50,777	Sep 24 07:41 PM
Reardon Andrew	Officer	Sep 23 '24	Proposed Sale	99.60	2,000	199,201		Sep 23 05:30 PM
Korenberg Matthew E	Officer	Sep 23 '24	Proposed Sale	101.50	14,437	1,465,403		Sep 23 05:27 PM
Korenberg Matthew E	Officer	Sep 20 '24	Proposed Sale	104.10	6,275	653,238		Sep 20 06:12 PM
Espinoza Octavio	Officer	Sep 20 '24	Proposed Sale	103.94	1,275	132,518		Sep 20 05:39 PM
Espinoza Octavio	Chief Financial Officer	Sep 17 '24	Option Exercise	79.63	1,486	118,328	25,885	Sep 19 05:50 PM
Korenberg Matthew E	President & COO	Sep 16 '24	Option Exercise	58.49	5,774	337,696	54,008	Sep 18 07:55 PM
Espinoza Octavio	Chief Financial Officer	Aug 28 '24	Option Exercise	66.52	753	50,086	24,399	Aug 30 09:00 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Option Exercise	52.27	1,500	78,405	24,034	Aug 30 08:56 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Sale	106.39	1,500	159,591	22,534	Aug 30 08:56 PM
Reardon Andrew	Officer	Aug 28 '24	Proposed Sale	106.39	1,500	159,590		Aug 28 04:39 PM
Korenberg Matthew E	President & COO	Aug 26 '24	Sale	105.61	11,389	1,202,831	49,510	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 23 '24	Sale	104.80	6,312	661,479	60,899	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 22 '24	Sale	105.54	1,157	122,110	67,211	Aug 26 08:15 PM
Korenberg Matthew E	Officer	Aug 22 '24	Proposed Sale	105.03	18,858	1,980,567		Aug 22 06:05 PM
Korenberg Matthew E	President & COO	Aug 09 '24	Sale	98.50	18,245	1,797,132	68,368	Aug 13 05:21 PM
Davis Todd C	Chief Executive Officer	Aug 08 '24	Buy	97.39	2,500	243,480	123,010	Aug 09 05:52 PM
Korenberg Matthew E	Officer	Aug 09 '24	Proposed Sale	98.50	18,245	1,797,132		Aug 09 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals, Inc

Upgrade your FINVIZ experience